News & Videos - ESPERITE - Page 5

CEO , Frédéric Amar will convert 1.5 million shares and will subscribe to 1 million new shares to support the business. Zutphen, The Netherlands - 2 October 2017 Esperite NV (Euronext: ESP, "Esperite" or "the Group") has published its financial results (unaudited) for the period of six months ended June 30, 2017 showing a decrease in total revenue to EUR 8.3 million, and cost of sales decreased by 48%. The negative EBITDA was balanced by the external financing which is expected to support the...

Zutphen, The Netherlands - 29 September 2017 Esperite N.V. (Euronext: ESP, the " Company " or " Esperite ") announces that the Company expects to publish its Interim Financial Reporting on or before 2 October 2017. About ESPERITE ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine established in 2000. *** This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014...

Zutphen, The Netherlands, 31 August 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the Seventh Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 200,892 share subscription warrants attached (the "Warrants"), under the financing agreement of up to EUR 13.0 million signed between the Group and the Investor on 8 March 2017 (the "Agreement"). The Notes and the Warrants...

Zutphen, The Netherlands, 11 August 2017 As of today, EUR 2,090,000 of notes out of the total commitment amounting to EUR 9 million have been converted into shares and EUR 250,000 of warrants out of a total potential amount of EUR 4.05 million have been exercised into shares by European Select Growth Opportunities Fund (the " Investor") , therefore strengthening the Group's equity. The Investor is willing to confirm its support to the development of Esperite and has agreed to subscribe for a new...

Zutphen, The Netherlands, 5 July 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a fourth Packed Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 250,000 share subscription warrants attached (the "Warrants"), under the financing agreement of up to EUR 13.0 million signed between the Group and the Investor on 8 March 2017 (the "Agreement"). The Notes and the Warrants...

Zutphen, The Netherlands, 15 June 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a third Packed Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 250,000 share subscription warrants attached (the "Warrants"), under the financing agreement of up to EUR 13.0 million signed between the Group and the Investor on 8 March 2017 (the "Agreement"). The Notes and the Warrants...

Zutphen, The Netherlands, 1 June 2017 As of today, 100% of the EUR 1.0 million initial tranche issued on March 8, 2017 has been converted into shares by European Select Growth Opportunities Fund (the " Investor") as well as the first of the four packed tranches referred to in our press release of yesterday, May 31 st 2017. Today a second tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " Notes ") with a principal amount of EUR 10,000 each, with 250,000 share...

Zutphen, The Netherlands, 31 May 2017 As of today, EUR 940,000 out of the EUR 1.0 million tranche issued on March 8, 2017 have been converted into shares by European Select Growth Opportunities Fund (the " Investor") , therefore strengthening the Group's equity. The Investor is willing to confirm its support to the development of Esperite and has agreed to subscribe for a new tranche of EUR 350,000 today upon request of Esperite, although the conditions required under the financing agreement of...

Zutphen, The Netherlands, 31 May 2017 As of today, EUR 940,000 out of the EUR 1.0 million tranche issued on March 8, 2017 have been converted into shares by European Select Growth Opportunities Fund (the " Investor") , therefore strengthening the Group's equity. The Investor is willing to confirm its support to the development of Esperite and has agreed to subscribe for a new tranche of EUR 350,000 today upon request of Esperite, although the conditions required under the financing agreement of...

EBITDA improved compared to budget as a result of cost control Zutphen, the Netherlands - 31 May 2017 Market Update Q1 2017 The Q1 actual consolidated revenue of Esperite was higher compared to budget. EBITDA for the same period also improved compared to budget as a result of cost control. CryoSave revenue was 6% higher compared to budget mainly due to changed country mix. The number of samples stored was in line with budget and the average price was higher compared to budget. Operating expenses...

Zutphen, the Netherlands - 31 May 2017 The unfortunate liquidation procedure against Genoma SA, ruled on May 4th 2017, for which an appeal is still pending, has triggered the obligation to repay Esperite note holders within 15 business days. The board has on May 26th 2017 proposed and negotiated the possible issuance of new notes to repay the note holders. The note holders, Educe Capital and Frederic Amar, have agreed their notes, for a total amount of EUR 3'125'000, to be repaid by the issuance...

Zutphen, The Netherlands - 23 May 2017 Esperite N.V. (Euronext: ESP, " Esperite ") announces that it has convened its Annual General Meeting of Shareholders (" AGM ") to be held on 4 July 2017 at 14:00 hours CET at Hotel NH Amsterdam Barbizon Palace, Prins Hendrikkade 59-72, 1012 AD, Amsterdam, The Netherlands. The AGM's convocation notice, agenda and the explanatory notes to the agenda and further AGM materials can be downloaded from Esperite's website ( www.esperite.com ) and are available...

Zutphen, the Netherlands - 23 May 2017 ESPERITE N.V. (Euronext: ESP, "Esperite" or "the Group") has published today its Annual Report for the year ended 31 December 2016. The 2016 Annual Report is now available on the Company's website www.esperite.com. CryoSave's EBITDA improved from € -2.5 million to € -0.7 million. Genoma's autonomous revenue increased by 80% up to a level of € 6.9 million. Esperite's consolidated revenue decreased by 4.5% to € 26.3 million. Consolidated revenues were...

Zutphen, The Netherlands - 20 May 2017 Esperite N.V. (Euronext: ESP, the " Company " or " Esperite ") announces that additional time is needed for the Company to publish its Annual Report for the fiscal year ended 31 December 2016. This further delay is a consequence of the recently announced court ordered bankruptcy of Genoma S.A., a Swiss wholly-owned subsidiary of Esperite, and the subsequent appeal lodged by Genoma against the court order. The Company's auditor, Ernst & Young Accountants...

Genoma has filed appeal to the decision of liquidation taken on May 4 th 2017. Genoma considers this decision arbitrary due to the circumstances of the commercial and legal relationship with Premaitha. Zutphen, The Netherlands, 19 May 2017 Genoma has concluded with Premaitha an agreement in March 15 th 2015 for the supply of the genetic test Iona. The implementation of this contract implied significant investment specifically related to the use of the IONA Kits. Genoma represented 65% of...

Zutphen, les Pays-Bas, 15 mai 2017 La dernière action de Premaitha contre Genoma démontre sa tentative désespérée de cacher au public la situation financière de Premaitha. L'effet de leur action en justice contre Genoma entraîne déjà une publicité négative, alors que la décision légale n'aura que peu d'effet dans les affaires du Groupe. Genoma a représenté 65% des activités de Premaitha en 2015/16. Pendant cette période, Premaitha a atteint 2,45 millions de GBP de revenus et...

Zutphen, Paesi Bassi, 15 maggio 2017 Le ultime mosse di Premaitha contro Genoma, dimostrano il suo disperato tentativo di nascondere la situazione finanziaria di Premaitha stessa. L'effetto dell'azione legale contro Genoma, genera già un danno per pubblicità negativa, mentre la decisione legale di per sé, difficilmente potrà interrompere l'attività di Genoma. Genoma rappresentava il 65% dell'attività di Premaitha nel 2015/16, quando Premaitha raggiungeva meno di 2,45 milioni di GBP di...

Zutphen, The Netherlands, 15 May 2017 Premaitha's latest action against Genoma demonstrates its desperate attempt to conceal Premaitha's financial situation. The effect of their legal action against Genoma already gives rise to negative publicity, while the legal decision in itself will hardly interrupt Genoma's business. Genoma represented 65% of Premaitha's business in 2015/16, when Premaitha reached 2.45 Million GBP of revenues and 12 Million GBP of losses. Genoma was forced to discontinue...

Zutphen, Países Bajos, 15 mayo 2017 La última acción llevada a cabo por Premaitha contra Genoma demuestra una desesperada intención de encubrir la situación financiera de Premaitha. Los efectos de las acciones legales puestas en marcha dan lugar a publicidad negativa , al tiempo que la decisión legal por si misma es incapaz de interrumpir el negocio de Genoma. Genoma representa el 65% del negocio de Premaitha durante los años 2015 y 2016, cuando Premaitha alcanza 2,45M GBP de beneficio y...

Zutphen, les Pays-Bas, 15 mai 2017 La dernière action de Premaitha contre Genoma démontre sa tentative désespérée de cacher au public la situation financière de Premaitha. L'effet de leur action en justice contre Genoma entraîne déjà une publicité négative, alors que la décision légale n'aura que peu d'effet dans les affaires du Groupe. Genoma a représenté 65% des activités de Premaitha en 2015/16. Pendant cette période, Premaitha a atteint 2,45 millions de GBP de revenus et...